文献速递消化系统肿瘤

奥拉帕利单药治疗携带非胚系BRCA的DDR基因改变晚期胰腺癌:两项2期非随机临床试验

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
PubMed 文献 · JAMA Oncol · 2021-01-01

两项平行2期非随机临床试验纳入46例可评估的晚期经治胰腺癌患者,均无胚系BRCA1/2变异但符合BRCAness定义。结论认为BRCAness表型或应限于携带DDR基因改变者,奥拉帕利耐受性好但抗肿瘤活性有限。

要点

  • 奥拉帕利单药在经治BRCAness胰腺癌中客观缓解率仅2%,中位无进展生存3.7个月。

核心结论

  • 在两项2期非随机临床试验中,奥拉帕利单药在晚期铂类敏感、携带DDR基因改变的经治胰腺癌患者中耐受性良好但抗肿瘤活性有限。
  • BRCAness表型在胰腺癌中可能应限于携带DDR基因改变的患者。

研究设计与样本

  • 两项平行2期非随机临床试验,2016年11月11日至2018年10月2日在以色列和德克萨斯开展。
  • 纳入标准为晚期胰腺癌接受过1线及以上系统治疗、ECOG体能状态0-1、无胚系BRCA1/2变异。
  • BRCAness定义为已知DDR基因改变、无DDR基因改变的BRCA相关肿瘤个人或家族史、或免疫组化ATM蛋白缺失。

主要发现

  • 奥拉帕利中位治疗时长3.0个月(四分位距1.8-6.4个月)。
  • 24例携带DDR基因改变,17例有BRCA相关肿瘤家族史但无DDR基因改变,5例免疫组化ATM蛋白缺失。
  • 1例确认部分缓解(2%),33例疾病稳定(72%),其中11例(24%)疾病稳定超过4个月,12例疾病进展(26%)。
  • 确认部分缓解者的缓解持续时间为3.9个月。

关键数值与推荐

  • DDR基因改变包括ATM(14例)、PALB2(2例)、ARID1A(3例)、BRCA体细胞(1例)、PTEN(1例)、RAD51(1例)、CCNE(1例)、FANCB(2例)。
  • 常见毒性为1-2级贫血、乏力、厌食和恶心。

临床怎么用

  • 对无胚系BRCA变异的晚期经治胰腺癌,可检测DDR基因改变以识别可能从奥拉帕利获益的BRCAness亚群。
  • 奥拉帕利单药在该人群中抗肿瘤活性有限,临床决策需结合DDR状态和铂类敏感性综合评估。

局限性

  • 两项2期非随机临床试验,样本量小(46例可评估),无对照组。
  • BRCAness定义包含异质性人群,各亚组样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The subtype of pancreatic ductal adenocarcinoma cancer (PDAC) with DNA damage repair (DDR) deficiency from BRCA1/2 variants has a favorable prognosis and is sensitive to platinum analogues and poly-(adenosine diphosphate-ripose) polymerase (PARP) inhibition with olaparib. Approximately 10% to 20% of patients with PDAC have DDR genetic alterations other than germline BRCA variants. This population has been termed as having BRCAness. An opportunity exists to define the clinical phenotype, molecular underpinnings, and effectiveness of PARP inhibitors for this population. OBJECTIVE: To examine the therapeutic effectiveness of the PARP inhibitor olaparib for patients with pancreatic cancer with BRCAness. DESIGN, SETTING, AND PARTICIPANTS: Two parallel phase 2 nonrandomized clinical trials were conducted from November 11, 2016, to October 2, 2018, among 46 patients in Israel and Texas to determine the effectiveness of olaparib as monotherapy in advanced, previously treated PDAC with BRCAness. Inclusion criteria were treatment with 1 or more prior systemic therapies for advanced PDAC, Eastern Cooperative Oncology Group performance status of 0 to 1, and lack of the germline BRCA1/2 variant. BRCAness in these studies was defined as previously known DDR genetic alterations (DDR-GAs), personal or family history of BRCA-associated cancers (without DDR-GAs), or ATM protein loss as determined by immunohistochemistry. MAIN OUTCOMES AND MEASURES: The primary study end point was the objective response rate, and the secondary end points were progression-free survival and overall survival (OS). RESULTS: Forty-eight patients were enrolled, and 46 (26 women [57%]; mean [SD] age, 65.5 [11.1] years) were evaluable. The median treatment duration with olaparib was 3.0 months (interquartile range, 1.8-6.4 months). A total of 24 patients had the DDR phenotype (DDR-GAs), 17 had a family history of BRCA-associated cancers without DDR-GAs, and 5 had ATM loss as determined by immunohistochemistry. The DDR-GAs included ATM (n = 14), PALB2 (n = 2), ARID1A (n = 3), BRCA somatic (n = 1), PTEN (n = 1), RAD51 (n = 1), CCNE (n = 1), and FANCB (n = 2). Common toxic effects were grade 1 to 2 anemia, fatigue, anorexia, and nausea. One patient had a confirmed partial response (2%), 33 patients experienced stable disease (72%), of whom 11 (24%) experienced disease stability longer than 4 months and 12 patients had progressive disease (26%). The response duration for the patient with confirmed partial response was 3.9 months. Median progression-free survival was 3.7 months (95% CI, 2.9-5.7) and was significantly higher for patients with DDR-GAs (5.7 months; 95% CI, 3.6-8.8 months; P = .008) and platinum-sensitive PDAC (4.1 months; 95% CI, 3.6-7.8 months; P = .01). The estimated median OS was 9.9 months (95% CI, 7.6-16.1 months) in the study and 13.6 months (95% CI, 9.69 to not reached) in the prespecified DDR-GA cohort. CONCLUSIONS AND RELEVANCE: The definition of the BRCAness phenotype in PDAC may be limited to patients harboring DDR-GAs. In these 2 phase 2 nonrandomized clinical trials, olaparib was well tolerated and showed limited antitumor activity in patients with advanced, platinum-sensitive PDAC with DDR-GAs. These conclusions suggest a potential therapeutic opportunity for a subset of patients with PDAC.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Javle M, Shacham-Shmueli E, Xiao L, et al. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. JAMA Oncol. 2021. PMID: 33662100. doi:10.1001/jamaoncol.2021.0006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。